FIELD: medicine； pharmaceuticals.SUBSTANCE: invention relates to compounds of formula (I) and pharmaceutically acceptable salts and stereoisomers thereof, which are inhibitors of IRAK. In the formula (I), R1 and R3, each independently of one another, mean H, (CH2)pCON(R5)2, OA, Hal, COOH, COOA, (CH2)pNHCOA, (CH2)PHet1, (CH2)pNR2R5 or OH； R2 is H or a linear or branched alkyl of 1, 2 or 3 carbon atoms； R4 is H or A； R5 is H or a linear or branched alkyl of 1, 2 or 3 carbon atoms； Z is absent or means Ar-diyl or Het-diyl； L is (CH2)n, where one or two CH2 groups can be replaced by O and/or CH=CH groups and/or where one or two H atoms can be replaced by OR2 or NR2R5； Ar-diyl is 1,2-, 1,3- or 1,4-phenylene optionally substituted by 1 to 5 groups independently selected from Hal, OH, OA, Het2 and/or A； Het-diyl means an unsaturated, saturated or aromatic 5- or 6-membered heterocycle having from 1 to 2 N, O and/or S atoms which may be unsubstituted or mono-, di- or trisubstituted by O-A and/or A； A is a linear or branched alkyl having from 1 to 10 carbon atoms in which one or two non-adjacent CH2 groups can be replaced by O； Het1 is morpholinyl； Het2 is morpholinyl； Hal is F, Cl, Br, I； n is 1, 2, 3, 4, 5, or 6； p means 0, 1 or 2. (I).EFFECT: invention also relates to particular compounds of formula (I), a pharmaceutical composition containing said compounds, and a method of synthesizing them.13 cl, 1 tbl, 45 exИзобретение относится к соединениям формулы (I) и их фармацевтически приемлемым солям и стереоизомерам, которые являются ингибиторами IRAK. В формуле (I) R1 и R3 каждый независимо друг от друга означают Н, (CH2)pCON(R5)2, OA, Hal, СООН, СООА, (CH2)pNHCOA, (CH2)PHet1, (CH2)pNR2R5 или ОН； R2 означает Н или линейный или разветвленный алкил с 1, 2 или 3 атомами углерода； R4 означает Н или А； R5 означает Н или линейный или разветвленный алкил с 1, 2 или 3 атомами углерода； Z отсутствует или означает Ar-диил или Het-диил； L означает (СН2)n, где одна или две группы СН2 мо
